

## **B. AMENDMENTS TO THE CLAIMS**

Claims 1-22 have been cancelled.

23. (New) A human-murine neutralizing antibody against respiratory syncytial virus which is specific for antigenic site A of respiratory syncytial virus F protein.

24. (New) The antibody of Claim 23 wherein said antibody contains at least one CDR from each of the variable heavy and variable light chains of a murine monoclonal antibody against respiratory syncytial virus.

25. (New) The antibody of Claim 24 wherein said antibody contains three CDRs from each of the heavy and variable light chains of a murine monoclonal antibody against respiratory syncytial virus.

26. (New) A method for preventing a respiratory syncytial virus infection in an animal, comprising:  
administering to said animal an effective amount of the antibody of Claim 23.

27. (New) A human-murine neutralizing antibody against respiratory syncytial virus which is specific for antigenic site C of respiratory syncytial virus F protein.

28. (New) The antibody of Claim 27 wherein said antibody contains at least one CDR from each of the variable heavy and light chains of a murine monoclonal antibody against respiratory syncytial virus.

29. (New) The antibody of Claim 28 wherein said antibody contains three CDRs from each of the variable heavy and light chains of a murine monoclonal antibody against respiratory syncytial virus.

30. (New) A method for preventing a respiratory syncytial virus infection in an animal, comprising:

administering to said animal an effective amount of the antibody of Claim 27.

31. (New) A human-murine neutralizing antibody against respiratory syncytial virus which is specific for respiratory syncytial virus F protein.

32. (New) The antibody of Claim 31 wherein said antibody contains at least one CDR from each of the variable heavy and variable light chains of a murine monoclonal antibody against respiratory syncytial virus.

33. (New) The antibody of Claim 32 wherein said antibody contains three CDRs from each of the variable heavy and light chains of a murine monoclonal antibody against respiratory syncytial virus.

34. (New) A method for preventing a respiratory syncytial virus infection in an animal, comprising:

administering to said animal an effective amount of the antibody of Claim 31.